Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
Seminal data from population genetics have presaged the development of several novel lipid-regulating drugs and the prospect of more effectively addressing high residual risk of cardiovascular disease (CVD) in patients receiving secondary prevention therapies [1]. The most impressive development is...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Published: |
Elsevier Ireland Ltd.
2018
|
| Online Access: | http://hdl.handle.net/20.500.11937/68873 |